Viking Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Viking Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues | ||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||
| research and development | 60,153,000 | 41,391,000 | 30,987,000 | 22,785,000 | 23,769,000 | 24,103,000 | 20,502,000 | 18,379,000 | 13,917,000 | 11,008,000 | 16,178,000 | 11,959,000 | 13,542,000 | 12,555,000 | 9,847,000 | 10,795,000 | 12,804,000 | 11,535,000 | 9,049,000 | 7,116,000 | 7,780,000 | 7,987,000 | 6,451,000 | 5,279,000 | 7,333,000 | 4,496,000 | 5,089,000 | 5,687,000 | 5,221,000 | 3,043,000 | 3,033,017 | 3,464,639 | 3,715,379 | 3,528,150 | 2,647,469 | 2,104,794 | 2,371,058 | 1,877,178 | 3,219,414 | 2,507,553 | 1,100,906 | 138,969 |
| general and administrative | 14,421,000 | 14,078,000 | 15,251,000 | 13,771,000 | 10,285,000 | 9,970,000 | 8,783,000 | 8,886,000 | 9,823,000 | 9,529,000 | 4,105,000 | 4,237,000 | 4,089,000 | 3,690,000 | 2,663,000 | 2,608,000 | 2,737,000 | 2,693,000 | 2,217,000 | 2,727,000 | 2,826,000 | 2,961,000 | 2,422,000 | 2,160,000 | 2,236,000 | 2,310,000 | 1,948,000 | 1,707,000 | 1,704,000 | 1,762,000 | 1,394,235 | 1,226,892 | 1,267,364 | 1,440,512 | 1,090,055 | 1,159,488 | 1,206,995 | 1,390,239 | 1,400,889 | 1,780,668 | 1,526,008 | 322,071 |
| total operating expenses | 74,574,000 | 55,469,000 | 46,238,000 | 36,556,000 | 34,054,000 | 34,073,000 | 29,285,000 | 27,265,000 | 23,740,000 | 20,537,000 | 20,283,000 | 16,196,000 | 17,631,000 | 16,245,000 | 12,510,000 | 13,403,000 | 15,541,000 | 14,228,000 | 11,266,000 | 9,843,000 | 10,606,000 | 10,948,000 | 8,873,000 | 7,439,000 | 9,569,000 | 6,806,000 | 7,037,000 | 7,394,000 | 6,925,000 | 4,805,000 | 4,427,252 | 4,691,531 | 4,982,743 | 4,968,662 | 3,737,524 | 3,264,282 | 3,578,053 | 3,267,417 | 4,620,303 | 4,288,221 | 2,626,914 | 461,040 |
| income from operations | -74,574,000 | -55,469,000 | -46,238,000 | -36,556,000 | -34,054,000 | -34,073,000 | -29,285,000 | -27,265,000 | -23,740,000 | -20,537,000 | -20,283,000 | -16,196,000 | -17,631,000 | -16,245,000 | -12,510,000 | -13,403,000 | -15,541,000 | -14,228,000 | -11,266,000 | -9,843,000 | -10,606,000 | -10,948,000 | -8,873,000 | -7,439,000 | -9,569,000 | -6,806,000 | -7,037,000 | -7,394,000 | -6,925,000 | -4,805,000 | -4,427,252 | -4,691,531 | -4,982,743 | -4,968,662 | -3,737,524 | -3,264,282 | -3,578,053 | -3,267,417 | -4,620,303 | -4,288,221 | -2,626,914 | -461,040 |
| yoy | 118.99% | 62.79% | 57.89% | 34.08% | 43.45% | 65.91% | 44.38% | 68.34% | 34.65% | 26.42% | 62.13% | 20.84% | 13.45% | 14.18% | 11.04% | 36.17% | 46.53% | 29.96% | 26.97% | 32.32% | 10.84% | 60.86% | 26.09% | 0.61% | 38.18% | 41.64% | 58.95% | 57.60% | 38.98% | -3.29% | 18.45% | 43.72% | 39.26% | 52.07% | -19.11% | -23.88% | 36.21% | 608.71% | ||||
| qoq | 34.44% | 19.96% | 26.49% | 7.35% | -0.06% | 16.35% | 7.41% | 14.85% | 15.60% | 1.25% | 25.23% | -8.14% | 8.53% | 29.86% | -6.66% | -13.76% | 9.23% | 26.29% | 14.46% | -7.19% | -3.12% | 23.39% | 19.28% | -22.26% | 40.60% | -3.28% | -4.83% | 6.77% | 44.12% | 8.53% | -5.63% | -5.84% | 0.28% | 32.94% | 14.50% | -8.77% | 9.51% | -29.28% | 7.74% | 63.24% | 469.78% | |
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||
| amortization of financing costs | -24,000 | -24,000 | -24,000 | -24,000 | -18,000 | -28,000 | -26,000 | -2,000 | -32,000 | -28,000 | -8,000 | -27,000 | -12,000 | -12,000 | -12,000 | 35,000 | -21,000 | -21,000 | -21,000 | -20,000 | -20,000 | -45,000 | -46,000 | -40,000 | -30,000 | -30,000 | -30,000 | -30,000 | -30,000 | -30,000 | -33,516 | -17,568 | -421,781 | -98,179 | -92,849 | -45,852 | ||||||
| interest income | 9,033,000 | 9,864,000 | 10,844,000 | 11,531,000 | 11,820,000 | 6,745,000 | 4,706,000 | 4,733,000 | 4,547,000 | 1,034,000 | 732,000 | 450,000 | 253,000 | 154,000 | 159,000 | 125,000 | 181,000 | 239,000 | 313,000 | 576,000 | 1,040,000 | 1,304,000 | 1,469,000 | 1,742,000 | 1,925,000 | 1,914,000 | 1,839,000 | 824,000 | 392,000 | 181,000 | 1,819 | 2,111 | ||||||||||
| realized gain on investments | 4,000 | 1,000 | 109,000 | 2,000 | 26,000 | -1,000 | 14,000 | 2,000 | 6,000 | |||||||||||||||||||||||||||||||||
| total other income | 9,013,000 | 9,840,000 | 10,821,000 | 11,616,000 | 11,804,000 | 6,717,000 | 4,680,000 | 4,731,000 | 4,515,000 | 1,006,000 | 724,000 | 423,000 | 199,000 | 142,000 | 154,000 | 160,000 | 160,000 | 218,000 | 318,000 | 555,000 | 1,034,000 | 1,261,000 | 1,423,000 | 1,708,000 | 1,895,000 | 1,882,000 | 1,797,000 | 794,000 | 253,000 | 1,254,000 | 342,779 | -1,408,127 | -188,891 | -253,238 | 92,915 | -543,149 | -114,740 | -319,571 | -470,660 | -448,323 | ||
| net income | -65,561,000 | -45,629,000 | -35,417,000 | -24,940,000 | -22,250,000 | -27,356,000 | -24,605,000 | -22,534,000 | -19,225,000 | -19,531,000 | -19,559,000 | -15,773,000 | -17,432,000 | -16,103,000 | -12,356,000 | -13,243,000 | -15,381,000 | -14,010,000 | -10,948,000 | -9,288,000 | -9,572,000 | -9,687,000 | -7,450,000 | -5,731,000 | -7,674,000 | -4,924,000 | -5,240,000 | -6,600,000 | -6,672,000 | -3,551,000 | -4,084,473 | -6,099,658 | -5,171,634 | -5,221,900 | -3,644,609 | -3,807,431 | -3,692,793 | -3,586,988 | -5,090,963 | -4,736,544 | -7,865,066 | -5,711,415 |
| yoy | 194.66% | 66.80% | 43.94% | 10.68% | 15.73% | 40.06% | 25.80% | 42.86% | 10.29% | 21.29% | 58.30% | 19.10% | 13.33% | 14.94% | 12.86% | 42.58% | 60.69% | 44.63% | 46.95% | 62.07% | 24.73% | 96.73% | 42.18% | -13.17% | 15.02% | 38.67% | 28.29% | 8.20% | 29.01% | -32.00% | 12.07% | 60.20% | 40.05% | 45.58% | -28.41% | -19.62% | -53.05% | -37.20% | ||||
| qoq | 43.68% | 28.83% | 42.01% | 12.09% | -18.67% | 11.18% | 9.19% | 17.21% | -1.57% | -0.14% | 24.00% | -9.52% | 8.25% | 30.33% | -6.70% | -13.90% | 9.79% | 27.97% | 17.87% | -2.97% | -1.19% | 30.03% | 29.99% | -25.32% | 55.85% | -6.03% | -20.61% | -1.08% | 87.89% | -13.06% | -33.04% | 17.94% | -0.96% | 43.28% | -4.28% | 3.10% | 2.95% | -29.54% | 7.48% | -39.78% | 37.71% | |
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss, net of tax: | ||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on securities | 26,000 | 563,000 | -2,252,000 | 3,902,000 | -699,000 | -1,125,000 | 437,000 | 221,000 | -417,000 | 501,000 | -203,250 | 111,000 | -29,000 | 19,000 | -85,000 | -8,000 | -379,000 | 1,145,000 | -824,000 | -145,000 | -82,000 | 288,000 | 374,000 | -24,250 | 30,000 | -38,000 | -16,211 | 2,442 | 1,500 | -607 | -755 | 649 | -6,591 | 7,175 | -2,522 | 7,613 | ||||||
| foreign currency translation gain | 24,000 | -14,500 | 2,000 | 26,000 | -17,000 | 31,000 | ||||||||||||||||||||||||||||||||||||
| comprehensive loss | -65,511,000 | -45,057,000 | -37,837,000 | -21,036,000 | -22,923,000 | -28,566,000 | -24,089,000 | -22,399,000 | -19,647,000 | -19,047,000 | -18,900,000 | -15,885,000 | -17,670,000 | -16,965,000 | -12,735,000 | -13,224,000 | -15,466,000 | -14,060,000 | -10,956,000 | -9,667,000 | -8,427,000 | -10,511,000 | -7,595,000 | -5,813,000 | -7,386,000 | -4,550,000 | -5,546,000 | -6,570,000 | -6,710,000 | -3,640,000 | -4,100,684 | -6,097,216 | -5,170,134 | -5,222,507 | -3,645,364 | -3,806,782 | -3,699,384 | -3,579,813 | -5,093,485 | -4,728,931 | -7,877,527 | |
| basic and diluted net income per share | -0.58 | -0.41 | -0.32 | -0.22 | -0.2 | -0.26 | -0.25 | -0.23 | -0.19 | -0.25 | -0.12 | -0.22 | -0.21 | -0.23 | -0.16 | -0.2 | -0.22 | -0.4 | -0.99 | -0.53 | -1.07 | -1.4 | ||||||||||||||||||||
| weighted-average shares used for eps calculation | 112,134 | 112,069 | 109,037 | 110,911 | 110,390 | 103,457 | 94,347 | 99,846 | 99,010 | 78,352 | 76,834 | 76,505,000 | 76,842,000 | 77,413,000 | 77,198 | 78,009,000 | 77,897,000 | 74,782,000 | 72,597 | 72,643,000 | 72,487,000 | 72,356,000 | 71,959 | 72,040,000 | 71,921,000 | 57,580 | 61,232,000 | 52,767,000 | 25,978,098 | 27,469,784 | 24,118,887 | 22,352,921 | 16,278,292 | 18,991,971 | 17,105,374 | 9,015,778 | 6,355,869 | 8,947,480 | 7,331,861 | 4,073,609 | ||
| foreign currency translation loss | 9,000 | -85,000 | 79,000 | -86,000 | -5,000 | 141,000 | -223,000 | -207,000 | ||||||||||||||||||||||||||||||||||
| realized loss on investments | -42,000 | -2,000 | ||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -160 | -210 | -230 | -210 | -137.5 | -170 | -200 | -190 | -97.5 | -130 | -130 | -130 | -62.5 | -80 | -110 | -80 | -110 | -130 | ||||||||||||||||||||||||
| unrealized loss on securities | -31,000 | -893,000 | -50,000 | -89,000 | -12,461 | |||||||||||||||||||||||||||||||||||||
| other comprehensive gain, net of tax: | ||||||||||||||||||||||||||||||||||||||||||
| change in fair value of debt conversion feature liability | 37,000 | 1,361,000 | 632,628 | -1,136,074 | 570,676 | 277,698 | 620,087 | -64,514 | 412,050 | 96,547 | -216,841 | -197,496 | 546,485 | 82,656 | ||||||||||||||||||||||||||||
| amortization of debt discount | -146,000 | -258,000 | -258,152 | -256,596 | -336,656 | -431,227 | -431,227 | -431,227 | -524,977 | -400,657 | -240,516 | -240,515 | 240,515 | 171,955 | ||||||||||||||||||||||||||||
| net income per common share | ||||||||||||||||||||||||||||||||||||||||||
| basic | -70 | -80 | ||||||||||||||||||||||||||||||||||||||||
| diluted | -70 | -100 | ||||||||||||||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | 112,134 | 112,069 | 109,037 | 110,911 | 110,390 | 103,457 | 94,347 | 99,846 | 99,010 | 78,352 | 76,834 | 76,505,000 | 76,842,000 | 77,413,000 | 77,198 | 78,009,000 | 77,897,000 | 74,782,000 | 72,597 | 72,643,000 | 72,487,000 | 72,356,000 | 71,959 | 72,040,000 | 71,921,000 | 57,580 | 61,232,000 | 52,767,000 | 25,978,098 | 27,469,784 | 24,118,887 | 22,352,921 | 16,278,292 | 18,991,971 | 17,105,374 | 9,015,778 | 6,355,869 | 8,947,480 | 7,331,861 | 4,073,609 | ||
| basic | 71,755,000 | 44,649,000 | ||||||||||||||||||||||||||||||||||||||||
| diluted | 71,755,000 | 45,306,000 | ||||||||||||||||||||||||||||||||||||||||
| interest expense | -1,130 | -1,530 | -3,096 | -1,556 | -1,813 | -15,461 | -13,303 | -10,312 | 29,814 | 35,253 | ||||||||||||||||||||||||||||||||
| change in fair value of accrued license fees | 4,421,338 | 4,960,511 | ||||||||||||||||||||||||||||||||||||||||
| other incomes: | ||||||||||||||||||||||||||||||||||||||||||
| total other incomes | 5,238,152 | 5,250,375 |
We provide you with 20 years income statements for Viking Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Viking Therapeutics stock. Explore the full financial landscape of Viking Therapeutics stock with our expertly curated income statements.
The information provided in this report about Viking Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.